Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets EXMKT - Delayed Quote USD

Neurogenesis, Inc. (NEUN)

Compare
0.0001
0.0000
(0.00%)
At close: April 11 at 4:00:00 PM EDT
Loading Chart for NEUN
  • Previous Close 0.0000
  • Open 0.0001
  • Bid --
  • Ask --
  • Day's Range 0.0001 - 0.0001
  • 52 Week Range 0.0001 - 0.0001
  • Volume 1,000
  • Avg. Volume 10,264
  • Market Cap (intraday) 8,226
  • Beta (5Y Monthly) -22.00
  • PE Ratio (TTM)
  • EPS (TTM) 0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm'd, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm'd/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. has a research collaboration with the University of Edinburgh for the development of various platform approaches to enable gene therapies. The company was founded in 1984 and is headquartered in League City, Texas.

www.neurogenesis.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NEUN

View More

Performance Overview: NEUN

Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NEUN
0.00%
S&P 500 (^GSPC)
8.81%

1-Year Return

NEUN
0.00%
S&P 500 (^GSPC)
3.16%

3-Year Return

NEUN
98.67%
S&P 500 (^GSPC)
21.55%

5-Year Return

NEUN
98.46%
S&P 500 (^GSPC)
92.25%

Compare To: NEUN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NEUN

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.90%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.07M

  • Net Income Avi to Common (ttm)

    -9.6k

  • Diluted EPS (ttm)

    0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: NEUN

View More

Company Insights: NEUN

Research Reports: NEUN

View More

People Also Watch